ヒストン脱アセチル化酵素阻害剤の世界市場レポート 2025年

ヒストン脱アセチル化酵素阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.9％で17億7,000万米ドルに成長します。予測期間の成長は、バイオテクノロジーへの投資拡大、高齢者人口の増加、有利な規制承認と医薬品承認プロセスの迅速化、ドラッグデリバリーシステムの改善、治療用途の拡大などに起因すると考えられます。予測期間における主な動向としては、患者の健康状態をモニターするウェアラブルデバイスの統合、ナノテクノロジーとドラッグデリバリー手法の革新、バイオマーカーの特定と検証の進歩、人工知能（AI）と機械学習、次世代シーケンサーなどが挙げられます。

がん罹患率の上昇がヒストン脱アセチル化酵素阻害剤市場の成長を牽引すると予想されます。このようながん患者の増加は、人口の高齢化、たばこ、食事、環境汚染物質などの危険因子への曝露の増加、早期かつ頻繁な発見につながる診断技術の進歩などの要因によるところが大きいです。ヒストン脱アセチル化酵素阻害剤は、クロマチン構造を変化させることでがんを治療し、がん抑制遺伝子を活性化し、がん遺伝子を抑制することで、がん細胞の細胞周期の停止とアポトーシスを引き起こします。例えば、2024年2月、世界保健機関（WHO）は、2050年には新たに約3,500万人のがん患者が発生し、2022年の推定2,000万人から77％増加すると予測しました。このように、がんの罹患率の増加がヒストン脱アセチル化酵素阻害剤市場を押し上げています。

ヒストン脱アセチル化酵素阻害剤市場の主要企業は、より多くの治療選択肢を提供し、患者の利便性とコンプライアンスを高めるため、経口ヒストン脱アセチル化酵素（HDAC）阻害薬などの革新的な製剤開発に注力しています。経口HDAC阻害剤は、遺伝子の制御に関与するHDAC酵素を標的とする経口服用薬であり、がんや炎症性疾患を含む様々な疾患の治療に使用できます。例えば、2024年3月、イタリアの製薬会社であるItalfarmaco S.p.A.は、経口HDAC阻害剤であるデュビザット（ジビノスタット）について、6歳以上のデュシェンヌ型筋ジストロフィー（DMD）患者の治療薬としてFDAの承認を取得しました。デュビザットは、炎症と線維化を抑制することで筋損傷を緩和し、同時に筋線維の再生を促進することで、DMDに伴う筋力低下の進行を遅らせる。今回の承認は、極めて重要な第3相試験であるEPIDYS試験に基づいており、デュビザット投与群ではプラセボ投与群に比べ、4段の階段昇降を完了するまでの時間が統計学的に有意に短縮しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ヒストン脱アセチル化酵素阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒストン脱アセチル化酵素阻害剤市場：成長率分析
• 世界のヒストン脱アセチル化酵素阻害剤市場の実績：規模と成長, 2019-2024
• 世界のヒストン脱アセチル化酵素阻害剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界ヒストン脱アセチル化酵素阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒストン脱アセチル化酵素阻害剤市場分類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クラスIヒストン脱アセチル化酵素（HDAC）
• クラスIIヒストン脱アセチル化酵素（HDAC）
• クラスIIIヒストン脱アセチル化酵素（HDAC）
• その他の分類
• 世界のヒストン脱アセチル化酵素阻害剤市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• その他の投与経路
• 世界のヒストン脱アセチル化酵素阻害剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル
• 世界のヒストン脱アセチル化酵素阻害剤市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 神経学
• その他の用途
• 世界のヒストン脱アセチル化酵素阻害剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界のヒストン脱アセチル化酵素阻害剤市場クラスIヒストン脱アセチル化酵素（HDAC）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HDAC1阻害剤
• HDAC2阻害剤
• HDAC3阻害剤
• HDAC8阻害剤
• 世界のヒストン脱アセチル化酵素阻害剤市場クラスIIヒストン脱アセチル化酵素（HDAC）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• HDAC4阻害剤
• HDAC5阻害剤
• HDAC6阻害剤
• HDAC7阻害剤
• HDAC9阻害剤
• HDAC10阻害剤
• 世界のヒストン脱アセチル化酵素阻害剤市場クラスIIIヒストン脱アセチル化酵素（HDAC）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サーチュイン1（SIRT1）阻害剤
• サーチュイン2（SIRT2）阻害剤
• サーチュイン3（SIRT3）阻害剤
• サーチュイン4（SIRT4）阻害剤
• サーチュイン5（SIRT5）阻害剤
• サーチュイン6（SIRT6）阻害剤
• サーチュイン7（SIRT7）阻害剤
• 世界のヒストン脱アセチル化酵素阻害剤市場、その他の分類のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二重作用HDAC阻害剤
• 汎HDAC阻害剤
• 選択的HDAC阻害剤
• 複合阻害剤（HDAC+その他のメカニズム）

第7章 地域別・国別分析

• 世界のヒストン脱アセチル化酵素阻害剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のヒストン脱アセチル化酵素阻害剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒストン脱アセチル化酵素阻害剤市場：競合情勢
• ヒストン脱アセチル化酵素阻害剤市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Karyopharm Therapeutics Inc.
• Syndax Pharmaceuticals Inc.
• MEI Pharma Inc.
• Italfarmaco S.p.A.
• Tokyo Chemical Industry Co. Ltd.
• InvivoGen Corp.
• Huya Bioscience International LLC
• Crystal Genomics Inc.
• Spectrum Pharmaceuticals Inc.
• Curis Inc.
• Celgene Corporation
• Celleron Therapeutics
• Medivir AB
• Onxeo SA
• Regenacy Pharmaceuticals Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒストン脱アセチル化酵素阻害剤市場2029：新たな機会を提供する国
• ヒストン脱アセチル化酵素阻害剤市場2029：新たな機会を提供するセグメント
• ヒストン脱アセチル化酵素阻害剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Histone deacetylase inhibitors are compounds that disrupt the function of histone deacetylases, which are enzymes responsible for removing acetyl groups from histone proteins. This disruption can lead to increased acetylation of histones, resulting in a more relaxed chromatin structure and changes in gene expression.

Histone deacetylase inhibitors are mainly classified into Class I, Class II, Class III, and other types. Histone deacetylases are a group of enzymes that remove acetyl groups from histone proteins, causing chromatin condensation and transcriptional repression. These inhibitors can be administered orally, via injection, and are available through hospital pharmacies, online pharmacies, retail pharmacies, among others. They are useful in various fields such as oncology and neurology, with end users including hospitals, home care settings, specialty clinics, and other facilities.

The histone deacetylase inhibitors market research report is one of a series of new reports from The Business Research Company that provides histone deacetylase inhibitors with a histone deacetylase inhibitors market share, detailed histone deacetylase inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the histone deacetylase inhibitors industry. This histone deacetylase inhibitors market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.2 billion in 2024 to $1.3 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to regulatory support and fast-track approvals, the growing prevalence of cancer, increased funding for cancer research, the expansion of therapeutic applications, and increased expenditure on healthcare infrastructure.

The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growing investment in biotechnology, the growing elderly population, favorable regulatory approvals and faster drug approval processes, improved drug delivery systems, and the expansion of therapeutic applications. Major trends in the forecast period include the integration of wearable devices to monitor patient health, innovations in nanotechnology and drug delivery methods, advances in identifying and validating biomarkers, artificial intelligence (AI) and machine learning, and next-generation sequencing.

The rising incidence of cancer is expected to drive the growth of the histone deacetylase inhibitors market. This increase in cancer cases is largely due to factors such as aging populations, higher exposure to risk factors such as tobacco, diet, and environmental pollutants, and advancements in diagnostic techniques that lead to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, which activates tumor suppressor genes and suppresses oncogenes, causing cell cycle arrest and apoptosis in cancer cells. For example, in February 2024, the World Health Organization predicted that approximately 35 million new cancer cases would occur in 2050, a 77% increase from the estimated 20 million cases in 2022. Thus, the growing incidence of cancer is boosting the histone deacetylase inhibitors market.

Major companies in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to provide more treatment options and enhance patient convenience and compliance. An oral HDAC inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and can be used to treat various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italian pharmaceutical company, received FDA approval for Duvyzat (givinostat), an oral HDAC inhibitor, for treating Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat mitigates muscle damage by reducing inflammation and fibrosis while promoting muscle fiber regeneration, slowing the progression of muscle deterioration associated with DMD. This approval was based on the pivotal phase 3 EPIDYS trial, which showed that patients on Duvyzat had a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.

In January 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Mirati Therapeutics Inc. for an undisclosed amount. This acquisition aims to significantly strengthen and diversify Bristol Myers' oncology portfolio, which includes the lung cancer medicine KRAZATI (adagrasib) and a leading KRAS and KRAS-enabling program with two Phase 1 candidates. The goal is to accelerate the development and delivery of innovative cancer treatments and enhance Bristol Myers' long-term growth in oncology. Mirati Therapeutics Inc. is a US-based targeted oncology company specializing in developing cancer therapeutics and histone deacetylase inhibitors.

Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC

North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the histone deacetylase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The histone deacetylase inhibitors market consists of sales of bioinformatics tools, cell culture systems, laboratory equipment, and diagnostic devices. The market value includes the value of related goods sold by the service provider or included within the service offering. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Histone Deacetylase Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on histone deacetylase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for histone deacetylase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The histone deacetylase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Classification: Class I Histone Deacetylases (HDACs); Class II Histone Deacetylases (HDACs); Class III Histone Deacetylases (HDACs); Other Classifications
• 2) By Route Of Administration: Oral; Injectable; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 4) By Application: Oncology; Neurology; Other Applications
• 5) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Suubsegments:
• 1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors; HDAC2 Inhibitors; HDAC3 Inhibitors; HDAC8 Inhibitors
• 2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors; HDAC5 Inhibitors; HDAC6 Inhibitors; HDAC7 Inhibitors; HDAC9 Inhibitors; HDAC10 Inhibitors
• 3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors; Sirtuin 2 (SIRT2) Inhibitors; Sirtuin 3 (SIRT3) Inhibitors; Sirtuin 4 (SIRT4) Inhibitors; Sirtuin 5 (SIRT5) Inhibitors; Sirtuin 6 (SIRT6) Inhibitors; Sirtuin 7 (SIRT7) Inhibitors
• 4) By Other Classifications: Dual-acting HDAC Inhibitors; Pan-HDAC Inhibitors; Selective HDAC Inhibitors; Combination Inhibitors (HDAC + Other Mechanisms)
• Companies Mentioned: Merck & Co. Inc.; AstraZeneca plc; Novartis AG; Eisai Co. Ltd.; Aurobindo Pharma Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Histone Deacetylase Inhibitors Market Characteristics

3. Histone Deacetylase Inhibitors Market Trends And Strategies

4. Histone Deacetylase Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Histone Deacetylase Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Histone Deacetylase Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Histone Deacetylase Inhibitors Market Growth Rate Analysis
• 5.4. Global Histone Deacetylase Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Histone Deacetylase Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Histone Deacetylase Inhibitors Total Addressable Market (TAM)

6. Histone Deacetylase Inhibitors Market Segmentation

• 6.1. Global Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Class I Histone Deacetylases (HDACs)
• Class II Histone Deacetylases (HDACs)
• Class III Histone Deacetylases (HDACs)
• Other Classifications
• 6.2. Global Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Other Routes Of Administration
• 6.3. Global Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.4. Global Histone Deacetylase Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Neurology
• Other Applications
• 6.5. Global Histone Deacetylase Inhibitors Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class I Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HDAC1 Inhibitors
• HDAC2 Inhibitors
• HDAC3 Inhibitors
• HDAC8 Inhibitors
• 6.7. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class II Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HDAC4 Inhibitors
• HDAC5 Inhibitors
• HDAC6 Inhibitors
• HDAC7 Inhibitors
• HDAC9 Inhibitors
• HDAC10 Inhibitors
• 6.8. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Class III Histone Deacetylases (HDACs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sirtuin 1 (SIRT1) Inhibitors
• Sirtuin 2 (SIRT2) Inhibitors
• Sirtuin 3 (SIRT3) Inhibitors
• Sirtuin 4 (SIRT4) Inhibitors
• Sirtuin 5 (SIRT5) Inhibitors
• Sirtuin 6 (SIRT6) Inhibitors
• Sirtuin 7 (SIRT7) Inhibitors
• 6.9. Global Histone Deacetylase Inhibitors Market, Sub-Segmentation Of Other Classifications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dual-acting HDAC Inhibitors
• Pan-HDAC Inhibitors
• Selective HDAC Inhibitors
• Combination Inhibitors (HDAC + Other Mechanisms)

7. Histone Deacetylase Inhibitors Market Regional And Country Analysis

• 7.1. Global Histone Deacetylase Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Histone Deacetylase Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Histone Deacetylase Inhibitors Market

• 8.1. Asia-Pacific Histone Deacetylase Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Histone Deacetylase Inhibitors Market

• 9.1. China Histone Deacetylase Inhibitors Market Overview
• 9.2. China Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Histone Deacetylase Inhibitors Market

• 10.1. India Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Histone Deacetylase Inhibitors Market

• 11.1. Japan Histone Deacetylase Inhibitors Market Overview
• 11.2. Japan Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Histone Deacetylase Inhibitors Market

• 12.1. Australia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Histone Deacetylase Inhibitors Market

• 13.1. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Histone Deacetylase Inhibitors Market

• 14.1. South Korea Histone Deacetylase Inhibitors Market Overview
• 14.2. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Histone Deacetylase Inhibitors Market

• 15.1. Western Europe Histone Deacetylase Inhibitors Market Overview
• 15.2. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Histone Deacetylase Inhibitors Market

• 16.1. UK Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Histone Deacetylase Inhibitors Market

• 17.1. Germany Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Histone Deacetylase Inhibitors Market

• 18.1. France Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Histone Deacetylase Inhibitors Market

• 19.1. Italy Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Histone Deacetylase Inhibitors Market

• 20.1. Spain Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Histone Deacetylase Inhibitors Market

• 21.1. Eastern Europe Histone Deacetylase Inhibitors Market Overview
• 21.2. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Histone Deacetylase Inhibitors Market

• 22.1. Russia Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Histone Deacetylase Inhibitors Market

• 23.1. North America Histone Deacetylase Inhibitors Market Overview
• 23.2. North America Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Histone Deacetylase Inhibitors Market

• 24.1. USA Histone Deacetylase Inhibitors Market Overview
• 24.2. USA Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Histone Deacetylase Inhibitors Market

• 25.1. Canada Histone Deacetylase Inhibitors Market Overview
• 25.2. Canada Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Histone Deacetylase Inhibitors Market

• 26.1. South America Histone Deacetylase Inhibitors Market Overview
• 26.2. South America Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Histone Deacetylase Inhibitors Market

• 27.1. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Histone Deacetylase Inhibitors Market

• 28.1. Middle East Histone Deacetylase Inhibitors Market Overview
• 28.2. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Histone Deacetylase Inhibitors Market

• 29.1. Africa Histone Deacetylase Inhibitors Market Overview
• 29.2. Africa Histone Deacetylase Inhibitors Market, Segmentation By Classification, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Histone Deacetylase Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Histone Deacetylase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Histone Deacetylase Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Histone Deacetylase Inhibitors Market Competitive Landscape
• 30.2. Histone Deacetylase Inhibitors Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis

31. Histone Deacetylase Inhibitors Market Other Major And Innovative Companies

• 31.1. Karyopharm Therapeutics Inc.
• 31.2. Syndax Pharmaceuticals Inc.
• 31.3. MEI Pharma Inc.
• 31.4. Italfarmaco S.p.A.
• 31.5. Tokyo Chemical Industry Co. Ltd.
• 31.6. InvivoGen Corp.
• 31.7. Huya Bioscience International LLC
• 31.8. Crystal Genomics Inc.
• 31.9. Spectrum Pharmaceuticals Inc.
• 31.10. Curis Inc.
• 31.11. Celgene Corporation
• 31.12. Celleron Therapeutics
• 31.13. Medivir AB
• 31.14. Onxeo SA
• 31.15. Regenacy Pharmaceuticals Inc

32. Global Histone Deacetylase Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Histone Deacetylase Inhibitors Market

34. Recent Developments In The Histone Deacetylase Inhibitors Market

35. Histone Deacetylase Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Histone Deacetylase Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Histone Deacetylase Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Histone Deacetylase Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer